AC Immune (NASDAQ:ACIU) Shares Cross Below 50-Day Moving Average of $3.84

AC Immune SA (NASDAQ:ACIU - Get Free Report) crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $3.84 and traded as low as $3.36. AC Immune shares last traded at $3.37, with a volume of 60,549 shares trading hands.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. BTIG Research assumed coverage on shares of AC Immune in a research report on Friday, May 31st. They issued a "buy" rating and a $8.00 price target for the company. StockNews.com raised shares of AC Immune from a "sell" rating to a "hold" rating in a report on Wednesday, May 8th.

AC Immune Trading Down 0.6 %

The stock has a market capitalization of $333.29 million, a PE ratio of -4.88 and a beta of 1.27. The stock's fifty day simple moving average is $3.81 and its 200-day simple moving average is $3.39.

Institutional Investors Weigh In On AC Immune

Hedge funds have recently made changes to their positions in the business. BVF Inc. IL raised its stake in shares of AC Immune by 96.2% during the 4th quarter. BVF Inc. IL now owns 14,571,236 shares of the company's stock worth $72,856,000 after purchasing an additional 7,142,857 shares during the period. Avidity Partners Management LP raised its stake in shares of AC Immune by 50.5% during the 4th quarter. Avidity Partners Management LP now owns 4,469,080 shares of the company's stock worth $22,345,000 after purchasing an additional 1,499,280 shares during the period. Platinum Investment Management Ltd. raised its stake in shares of AC Immune by 14.6% during the 4th quarter. Platinum Investment Management Ltd. now owns 1,515,585 shares of the company's stock worth $7,578,000 after purchasing an additional 193,123 shares during the period. BNP Paribas Financial Markets raised its stake in shares of AC Immune by 315.6% during the 1st quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company's stock worth $33,000 after purchasing an additional 8,423 shares during the period. Finally, Nixon Peabody Trust Co. bought a new stake in shares of AC Immune during the 4th quarter worth $64,000. 51.36% of the stock is currently owned by institutional investors.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.